There is an urgent need for effective countermeasures against the current emergence and
accelerating expansion of coronavirus disease 2019 (COVID-19), caused by severe acute …

The current COVID‐19 pandemic has a tremendous impact on daily life world‐wide. Despite
the ability to dampen the spread of SARS‐CoV‐2, the causative agent of the diseases …

A recombinant vaccine containing Aventis Pasteur's canarypox vector (ALVAC)–HIV and
gp120 alum decreased the risk of HIV acquisition in the RV144 vaccine trial. The substitution …

For more than 50 years, heat shock proteins (HSPs) have been studied for their role in
protecting cells from elevated temperature and other forms of stress. More recently, several …

Qualitative differences in the innate and adaptive responses elicited by different HIV vaccine
candidates have not been thoroughly investigated. We tested the ability of the Aventis …

Many viral infections, including HIV, exhibit sex-based pathogenic differences. However, few
studies have examined vaccine-related sex differences. We compared immunogenicity and …

With the much-debated exception of the modestly reduced acquisition reported for the
RV144 efficacy trial, HIV-1 vaccines have not protected humans against infection, and a …

The lack of relevant animal models is the major bottleneck for understanding human
immunology and immunopathology. In the last few years, a novel model of humanized …

Over the past decade, our laboratory has developed a secreted heat shock protein (HSP),
chaperone gp96, cell-based vaccine that generates effective anti-tumor and anti-infectious …

The heat shock protein gp96 elicits specific T cell responses to its chaperoned peptides
against cancer and infectious diseases in both rodent models and clinical trials. Although …